Stockscreener 앱 받기
8.53
1.61%
-0.14
시간 외 거래:
8.70
0.17
+1.99%
Actuate Therapeutics Inc 주식(ACTU)의 최신 뉴스
Actuate Therapeutics Inc. Stages Intraday Comeback — Trend ChangeStock Surge & Verified Entry Point Detection - 선데이타임즈
Detecting price anomalies in Actuate Therapeutics Inc. with AI2025 Price Targets & Free Real-Time Volume Trigger Notifications - Newser
Forecasting Actuate Therapeutics Inc. price range with options dataJuly 2025 Market Mood & Low Drawdown Investment Strategies - Newser
How institutional ownership impacts Actuate Therapeutics Inc. stockJuly 2025 EndofMonth & Risk Adjusted Buy and Sell Alerts - Newser
Why Actuate Therapeutics Inc. is moving todayJuly 2025 Institutional & Fast Gain Stock Trading Tips - Newser
Regression analysis insights on Actuate Therapeutics Inc. performanceWeekly Loss Report & Daily Chart Pattern Signal Reports - Newser
Will Actuate Therapeutics Inc. stock split in the near future2025 Retail Activity & Weekly High Momentum Picks - Newser
Is a relief rally coming for Actuate Therapeutics Inc. holdersJuly 2025 Outlook & AI Optimized Trade Strategies - Newser
What the charts say about Actuate Therapeutics Inc. todayMarket Growth Summary & Daily Chart Pattern Signals - Newser
Published on: 2025-08-13 05:24:46 - 선데이타임즈
Should you hold or exit Actuate Therapeutics Inc. nowLong Term Stock Growth Plan Suggestions - Newser
Smart tools for monitoring Actuate Therapeutics Inc.’s price actionHistorical Stock Summary and ROI Review - Newser
Why Actuate Therapeutics Inc. stock attracts strong analyst attentionFree Proven Entry Plan With Low Risk Trade - Newser
Has Actuate Therapeutics Inc. found a price floorProfitable Trading Blueprint with Entry Zones - Newser
Will Actuate Therapeutics Inc. stock recover after recent dropChart Scanner for Swing Trade Timing - Newser
Risk adjusted return profile for Actuate Therapeutics Inc. analyzedChart Scanner for Swing Trade Timing - Newser
Backtesting results for Actuate Therapeutics Inc. trading strategiesDaily Market Movers Screener with Filters - Newser
Tick level data insight on Actuate Therapeutics Inc. volatilityChart Signal and Short-Term Forecast Tracker - Newser
Actuate Therapeutics Inc. stock momentum explainedTechnical Screener for High Growth Stocks - Newser
Fermented Stevia Extract Shows Promise in Fighting Pancreatic Cancer in Lab Tests - AInvest
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer - The Globe and Mail
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double - The Globe and Mail
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer - The Globe and Mail
What makes Actuate Therapeutics Inc. stock price move sharplyRSI and MACD Signal Summary with Trends - Newser
Actuate Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingInvestment Timing Strategy with Market Filters - Newser
Hillman Solutions Corp shares rise 3.41% intraday after Actuate Therapeutics announced a clinical trial collaboration with UPMC Hillman Cancer Center. - AInvest
Actuate, Incyte, University of Pittsburgh collaborate on elraglusib trial - TipRanks
Actuate Therapeutics to collaborate with Incyte Corporation on clinical trials - MarketScreener
Actuate Therapeutics To Collaborate with Incyte Corporation - GlobeNewswire
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer - Yahoo Finance
Does Actuate Therapeutics Inc. fit your quant trading modelExit Strategy Guide With Risk Control Plan - Newser
Ewing Sarcoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Nanovalent Pharma, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc - Barchart.com
Candlestick Signal Suggests Reversal in Actuate Therapeutics Inc.Fast Exit and Entry Strategy Guide Offered - beatles.ru
What drives Actuate Therapeutics Inc. stock priceBuild wealth faster with consistent investment plans - Jammu Links News
Actuate Therapeutics Inc. Stock Analysis and ForecastBuild a diversified portfolio for steady growth - Jammu Links News
What is the dividend policy of Actuate Therapeutics Inc. stockAchieve consistent profits with proven strategies - Jammu Links News
Is Actuate Therapeutics Inc. a growth stock or a value stockFree Expert Stock Watchlist - Jammu Links News
Is it the right time to buy Actuate Therapeutics Inc. stockAchieve superior returns with professional insights - Jammu Links News
Is Actuate Therapeutics Inc. a good long term investmentCapitalize on fast-growing stocks today - Jammu Links News
What are analysts’ price targets for Actuate Therapeutics Inc. in the next 12 monthsSuperior portfolio returns - Jammu Links News
What catalysts could drive Actuate Therapeutics Inc. stock higher in 2025Invest confidently with real-time market updates - Jammu Links News
What MACD signals say about Actuate Therapeutics Inc.7-Day Equity Return Range Forecast Model - Newser
What are Actuate Therapeutics Inc. company’s key revenue driversInvest confidently with professional market insights - Jammu Links News
What is the risk reward ratio of investing in Actuate Therapeutics Inc. stock - Jammu Links News
1.67%
자본화:
|
볼륨(24시간):